Quench Medical is developing novel formulations of approved inhaler medications to significantly decrease symptoms of lung diseases. Our platform technology is able to address the entire $40 billion inhaler market. The first indication is severe asthma, where patients suffer costly exacerbations from uncontrolled symptoms.

About Image

Bryce Beverlin II, PhD

Bryce is a physicist entrepreneur, passionately solving unmet needs in inflammatory lung diseases. As an asthmatic child, Bryce experienced the frightening desperation of an asthma attack. A strong desire to help fellow patients has motivated him to develop a next-generation aerosol medicine treatment.

Bryce has over a decade of R&D experience with post-doctoral commercialization training at the Medical Devices Center and as a physics Ph.D. student in a biomedical engineering lab at the University of Minnesota.

Bryce has surrounded himself with veteran advisers who have collectively raised over $500 million and held chief positions in successfully exited medical companies. Quench Medical’s clinical board includes the world’s top pulmonologists in small airway disease treatment and strong collaborators at top research institutions.


A $225k SBIR grant from the National Institutes of Health awarded in March 2018.

Quench Medical has completed the inaugural cohort of gBETA Medtech, sponsored by Boston Scientific, Mayo Clinic, and the University of Minnesota. gBETA is a free, seven-week accelerator for early-stage companies with local roots, started by nationally ranked startup accelerator gener8tor.

Currently Quench is raising the seed round and moving toward showing benefit in humans as quickly as possible.


Beverlin @ QuenchMedical.net